Type 2 & other diabetes

Global trans-lesional computed tomography-derived fractional flow reserve gradient is associated with clinical outcomes in diabetic patients with non-obstructive coronary artery disease

Cardiovasc DiabetolPublished Prospective cohort study

Main finding · MACEResult — go to the resultHazard ratio 2.86 95% CI 1.75–4.68

Authors' conclusion

In diabetic patients with non-obstructive CAD, GΔCT-FFR was associated with clinical outcomes at 5 year follow-up, which illuminates a novel and feasible approach to improved risk stratification for a global hemodynamic assessment of coronary artery in diabetic patients.

Study context

Population
Patients with diabetes suspected of having coronary artery disease (CAD); mean age 60.1 ± 10.3 years, 53.7% male
Participants
1,215 patients
Exposure
High vs low global trans-lesional CT-FFR gradient (GΔCT-FFR) without flow-limiting stenosis
Outcome
MACE
Follow-up
Median 57.3 months
Methodological detailsprospective enrolment
  • Prospective enrolment

Main finding

As reported in the abstract

Hazard ratio

2.86

95% CI 1.75–4.68

P < 0.001

High-gradient without flow-limitingvs Low-gradient without flow-limiting
HR 2.86 (95% CI 1.75–4.68); P < 0.001
Major adverse cardiovascular events (MACE) incidence, overall
11.3%
GΔCT-FFR, independent risk factor of MACE in multivariable analysis: HR
2.88 (95% CI 1.76-4.70, P < 0.001)

Observational data: associations, not effects.

Further findings

Incremental prognostic value of GΔCT-FFR among 4 risk models

Model 4 (incl. GΔCT-FFR) highest C-statistic (P = 0.002)
0.75
Net reclassification improvement (NRI) of model 4 beyond model 3 (P < 0.001)
0.605

Original publication

Global trans-lesional computed tomography-derived fractional flow reserve gradient is associated with clinical outcomes in diabetic patients with non-obstructive coronary artery disease. Cardiovasc Diabetol. Published 26 July 2023. doi:10.1186/s12933-023-01901-9

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.